Cargando…

Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer

BACKGROUND: Tumor infiltrating lymphocytes (TILs) reflect adaptive antitumor immune responses in cancer and are generally associated with favorable prognosis. However, the relationships between TILs subsets and their spatial arrangement with clinical benefit from immune checkpoint inhibitors (ICI) i...

Descripción completa

Detalles Bibliográficos
Autores principales: Lopez de Rodas, Miguel, Nagineni, Venkata, Ravi, Arvind, Datar, Ila J, Mino-Kenudson, Mari, Corredor, German, Barrera, Cristian, Behlman, Lindsey, Rimm, David L, Herbst, Roy S, Madabhushi, Anant, Riess, Jonathan W, Velcheti, Vamsidhar, Hellmann, Matthew D, Gainor, Justin, Schalper, Kurt A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161072/
https://www.ncbi.nlm.nih.gov/pubmed/35649657
http://dx.doi.org/10.1136/jitc-2021-004440
_version_ 1784719409040850944
author Lopez de Rodas, Miguel
Nagineni, Venkata
Ravi, Arvind
Datar, Ila J
Mino-Kenudson, Mari
Corredor, German
Barrera, Cristian
Behlman, Lindsey
Rimm, David L
Herbst, Roy S
Madabhushi, Anant
Riess, Jonathan W
Velcheti, Vamsidhar
Hellmann, Matthew D
Gainor, Justin
Schalper, Kurt A
author_facet Lopez de Rodas, Miguel
Nagineni, Venkata
Ravi, Arvind
Datar, Ila J
Mino-Kenudson, Mari
Corredor, German
Barrera, Cristian
Behlman, Lindsey
Rimm, David L
Herbst, Roy S
Madabhushi, Anant
Riess, Jonathan W
Velcheti, Vamsidhar
Hellmann, Matthew D
Gainor, Justin
Schalper, Kurt A
author_sort Lopez de Rodas, Miguel
collection PubMed
description BACKGROUND: Tumor infiltrating lymphocytes (TILs) reflect adaptive antitumor immune responses in cancer and are generally associated with favorable prognosis. However, the relationships between TILs subsets and their spatial arrangement with clinical benefit from immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) remains less explored. METHODS: We used multiplexed quantitative immunofluorescence panels to determine the association of major TILs subpopulations, CD8(+) cytotoxic T cells, CD4(+) helper T cells and CD20(+) B cells, and T cell exhaustion markers, programmed cell death protein-1 (PD-1), lymphocyte-activation gene 3 (LAG-3) and T cell immunoglobulin mucin-3 (TIM-3) with outcomes in a multi-institutional cohort of baseline tumor samples from 179 patients with NSCLC treated with ICI. The analysis of full-face tumor biopsies including numerous fields of view allowed a detailed spatial analysis and assessment of tumor immune heterogeneity using a multiparametric quadratic entropy metric (Rao’s Q Index (RQI)). RESULTS: TILs were preferentially located in the stromal tissue areas surrounding tumor-cell nests and CD8(+) T cells were the most abundant subset. Higher density of stromal CD8(+) cytotoxic T cells was significantly associated with longer survival, and this effect was more prominent in programmed death ligand-1 (PD-L1) positive cases. The role of baseline T cell infiltration to stratify PD-L1 expressing cases was confirmed measuring the T cell receptor-burden in an independent NSCLC cohort studied with whole-exome DNA sequencing. High levels of LAG-3 on T cells or elevated RQI heterogeneity index were associated with worse survival in the cohort. CONCLUSION: Baseline T cell density and T cell exhaustion marker expression can stratify outcomes in PD-L1 positive patients with NSCLC treated with ICI. Spatial immune heterogeneity can be measured using the RQI and is associated with survival in NSCLC.
format Online
Article
Text
id pubmed-9161072
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-91610722022-06-16 Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer Lopez de Rodas, Miguel Nagineni, Venkata Ravi, Arvind Datar, Ila J Mino-Kenudson, Mari Corredor, German Barrera, Cristian Behlman, Lindsey Rimm, David L Herbst, Roy S Madabhushi, Anant Riess, Jonathan W Velcheti, Vamsidhar Hellmann, Matthew D Gainor, Justin Schalper, Kurt A J Immunother Cancer Immunotherapy Biomarkers BACKGROUND: Tumor infiltrating lymphocytes (TILs) reflect adaptive antitumor immune responses in cancer and are generally associated with favorable prognosis. However, the relationships between TILs subsets and their spatial arrangement with clinical benefit from immune checkpoint inhibitors (ICI) in non-small cell lung cancer (NSCLC) remains less explored. METHODS: We used multiplexed quantitative immunofluorescence panels to determine the association of major TILs subpopulations, CD8(+) cytotoxic T cells, CD4(+) helper T cells and CD20(+) B cells, and T cell exhaustion markers, programmed cell death protein-1 (PD-1), lymphocyte-activation gene 3 (LAG-3) and T cell immunoglobulin mucin-3 (TIM-3) with outcomes in a multi-institutional cohort of baseline tumor samples from 179 patients with NSCLC treated with ICI. The analysis of full-face tumor biopsies including numerous fields of view allowed a detailed spatial analysis and assessment of tumor immune heterogeneity using a multiparametric quadratic entropy metric (Rao’s Q Index (RQI)). RESULTS: TILs were preferentially located in the stromal tissue areas surrounding tumor-cell nests and CD8(+) T cells were the most abundant subset. Higher density of stromal CD8(+) cytotoxic T cells was significantly associated with longer survival, and this effect was more prominent in programmed death ligand-1 (PD-L1) positive cases. The role of baseline T cell infiltration to stratify PD-L1 expressing cases was confirmed measuring the T cell receptor-burden in an independent NSCLC cohort studied with whole-exome DNA sequencing. High levels of LAG-3 on T cells or elevated RQI heterogeneity index were associated with worse survival in the cohort. CONCLUSION: Baseline T cell density and T cell exhaustion marker expression can stratify outcomes in PD-L1 positive patients with NSCLC treated with ICI. Spatial immune heterogeneity can be measured using the RQI and is associated with survival in NSCLC. BMJ Publishing Group 2022-06-01 /pmc/articles/PMC9161072/ /pubmed/35649657 http://dx.doi.org/10.1136/jitc-2021-004440 Text en © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Immunotherapy Biomarkers
Lopez de Rodas, Miguel
Nagineni, Venkata
Ravi, Arvind
Datar, Ila J
Mino-Kenudson, Mari
Corredor, German
Barrera, Cristian
Behlman, Lindsey
Rimm, David L
Herbst, Roy S
Madabhushi, Anant
Riess, Jonathan W
Velcheti, Vamsidhar
Hellmann, Matthew D
Gainor, Justin
Schalper, Kurt A
Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
title Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
title_full Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
title_fullStr Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
title_full_unstemmed Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
title_short Role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to PD-1 axis blockers in non-small cell lung cancer
title_sort role of tumor infiltrating lymphocytes and spatial immune heterogeneity in sensitivity to pd-1 axis blockers in non-small cell lung cancer
topic Immunotherapy Biomarkers
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9161072/
https://www.ncbi.nlm.nih.gov/pubmed/35649657
http://dx.doi.org/10.1136/jitc-2021-004440
work_keys_str_mv AT lopezderodasmiguel roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer
AT naginenivenkata roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer
AT raviarvind roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer
AT datarilaj roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer
AT minokenudsonmari roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer
AT corredorgerman roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer
AT barreracristian roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer
AT behlmanlindsey roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer
AT rimmdavidl roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer
AT herbstroys roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer
AT madabhushianant roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer
AT riessjonathanw roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer
AT velchetivamsidhar roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer
AT hellmannmatthewd roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer
AT gainorjustin roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer
AT schalperkurta roleoftumorinfiltratinglymphocytesandspatialimmuneheterogeneityinsensitivitytopd1axisblockersinnonsmallcelllungcancer